Why the study?
Does genotype-guided warfarin dosing improve outcomes compared to clinical-guided dosing in patients initiating warfarin therapy?
Population
Patients requiring initiation of warfarin therapy (planned n=1238)
Comparison
Genotype-guided dosing of warfarin vs Clinical-guided dosing of warfarin
Design
Other, randomized, double blind
Authors
Loading...
Power calculations for genotype-guided warfarin dosing require realistic prevalence and effect assumptions; extends trial design standards in pharmacogenetics.
Does genotype-guided warfarin dosing improve outcomes compared to clinical-guided dosing in patients initiating warfarin therapy?
The statistical design of personalized medicine trials like COAG requires careful consideration of the prevalence of genetic variants and their relative effectiveness, as these assumptions heavily impact sample size and power.
French et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: